13/11/2025
Last Friday, more than 100 guests joined our MIND Foundation × OVID Clinic symposium at Berlin Science Week to discuss a milestone for psychedelic therapy: Germany’s first Compassionate Use program for psilocybin.
🎙️ Andrea Jungaberle opened the event with a clear statement:
“What we have here in Germany is the first true Compassionate Use program in the European Union.”
It is a regulatory breakthrough—and a major responsibility.
Many patients with long treatment histories now have reason to hope.
Yet compassionate use is not broad access, and even when treatment becomes available, success is not guaranteed.
As psilocybin-assisted psychotherapy providers, we carry full responsibility, including managing patients’ expectations.
Marvin Däumichen and Inna Krylovetska continued by exploring the cognitive, philosophical, and social dimensions of psychedelic experience.
They emphasized that psychedelics can increase both the frequency and the felt truth of insights—including false ones, which may lead to false beliefs—and why community and integration are essential:
“Hearing in an integration circle that someone else has gone through a similar experience can offer incredible support.”
📊 Christopher Schmidt presented new qualitative data from his PhD research and the EPIsoDE Study,
and Dr. Henrik Jungaberle outlined the next major step:
The DiMension Trial, a Phase III HTA study comparing psilocybin-assisted psychotherapy with antidepressant-based treatment.
This evidence will be key to integrating psychedelic therapy into public health care.
💡 As a non-profit organization preparing such a large study, we are still looking for additional philanthropic funders that want to support a breakthrough innovation in mental health.
The session concluded with a lively panel discussion on clinicians’ experiences with psychedelic therapy.
Later, MIND Members gathered for dinner, closing an intense and inspiring day with social connection :)
